Open access
Open access
Powered by Google Translator Translator

Daily Archives: December 1, 2020

IDSA 2020 Guidelines for the prevention, diagnosis and treatment of Lyme disease

1 Dec, 2020 | 08:28h | UTC

Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease – Clinical Infectious Diseases

Commentary: IDSA, AAN, and ACR Release Guidelines for Prevention, Diagnosis, and Treatment of Lyme Disease – Infectious Diseases Society of America

 


WHO World malaria report 2020: 20 years of global progress & challenges

1 Dec, 2020 | 08:27h | UTC

World malaria report 2020: 20 years of global progress & challenges – World Health Organization

News Release: WHO calls for reinvigorated action to fight malaria

 


Cohort study: Higher dose Z-drug use in dementia is associated with increased fracture and stroke risks, similar or greater to that for higher dose benzodiazepines

1 Dec, 2020 | 08:25h | UTC

Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study – BMC Medicine

Commentary: The danger of Z-drugs for dementia patients – University of Exeter

 


NICE COVID-19 guideline: Prevention of thromboembolism in patients with COVID-19. “For patients who are having advanced respiratory support: consider increasing pharmacological VTE prophylaxis to an intermediate dose”

1 Dec, 2020 | 08:19h | UTC

COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 – National Institute for Health and Care Excellence

 


Moderna released more Covid-19 vaccine results. They’re very encouraging.

1 Dec, 2020 | 08:15h | UTC

Moderna released more Covid-19 vaccine results. They’re very encouraging. – Vox

News release: Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

Commentaries: ‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19 – Science AND Moderna to submit Covid-19 vaccine to FDA as full results show 94% efficacy – STAT AND More Good News For Moderna’s COVID-19 Vaccine Candidate – NPR AND Moderna to seek emergency authorization for COVID-19 vaccine – CIDRAP

 

Commentary on Twitter

 


Comprehensive review on the management of pharmaceutical and recreational drug poisoning

1 Dec, 2020 | 08:21h | UTC

Management of pharmaceutical and recreational drug poisoning – Annals of Intensive Care

 


Opinion: How Prestige Journals Remain Elite, Exclusive and Exclusionary. “by announcing a €9,500 price tag, Nature has failed to enact their own diversity and inclusion pledge”

1 Dec, 2020 | 08:22h | UTC

How Prestige Journals Remain Elite, Exclusive And Exclusionary – Forbes

See also: For €9500, Nature journals will now make your paper free to read

 


Opinion: Pfizer and Moderna’s “95% effective” vaccines—let’s be cautious and first see the full data

1 Dec, 2020 | 08:13h | UTC

Peter Doshi: Pfizer and Moderna’s “95% effective” vaccines—let’s be cautious and first see the full data – BMJ Opinion

 


Colchicine to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

1 Dec, 2020 | 08:08h | UTC

Colchicine to be investigated as a possible treatment for COVID-19 in the RECOVERY trial – University of Oxford

Commentary: Gout drug Colchicine to be tested as COVID-19 treatment in UK trial – Reuters

 


Critically ill patients with COVID-19: A narrative review on prone position

1 Dec, 2020 | 08:07h | UTC

Critically Ill Patients with COVID-19: A Narrative Review on Prone Position – Pulmonary Therapy

 


The Ioannidis affair: A tale of major scientific overreaction

1 Dec, 2020 | 08:10h | UTC

The Ioannidis Affair: A Tale of Major Scientific Overreaction – Scientific American

 


The COVID science wars: Shutting down scientific debate is hurting the public health

1 Dec, 2020 | 08:11h | UTC

The COVID Science Wars – Scientific American

 


AstraZeneca vaccine most attractive option for Africa, says WHO – Astra Zeneca CEO says company will run new trial to test more efficient dose

1 Dec, 2020 | 08:05h | UTC

AstraZeneca Vaccine Most Attractive Option For Africa, Says WHO – Astra Zeneca CEO Says Company Will Run New Trial To Test More Efficient Dose – Health Policy Watch

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.